Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0026764 (
multiple myeloma
)
36,148
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Multiple myeloma
(MM) is an incurable neoplasm caused by proliferation of malignant plasma cells in the bone marrow (BM). MM is characterized frequently by a complete or partial deletion of chromosome 13q14, seen in more than 50% of patients at diagnosis. Within this deleted region the tripartite motif containing 13 (
TRIM13
, also termed RFP2) gene product has been proposed to be a tumour suppressor gene (TSG). Here, we show that low expression levels of
TRIM13
in MM are associated with chromosome 13q deletion and poor clinical outcome. We present a functional analysis of
TRIM13
using a loss-of-function approach, and demonstrate that
TRIM13
downregulation decreases tumour cell survival as well as cell cycle progression and proliferation of MM cells. In addition, we provide evidence for the involvement of
TRIM13
downregulation in inhibiting the NF kappa B pathway and the activity of the 20S proteasome. Although this data does not support a role of
TRIM13
as a TSG, it substantiates important roles of
TRIM13
in MM tumour survival and proliferation, underscoring its potential role as a novel target for therapeutic intervention.
...
PMID:TRIM13 (RFP2) downregulation decreases tumour cell growth in multiple myeloma through inhibition of NF Kappa B pathway and proteasome activity. 2364 56
